CELLforCURE gathers all cell and gene therapies activities of the LFB group. With an annual production capability of several thousands of therapeutics batches, the Les Ulis CELLforCURE facility is the first modular entity in Europe to enable large scale industrial production for ATMPs. This platform operates on a mixed model of a CDMO (Contract Development and Manufacturing Organisation) providing large scale GMP and cGMP production services, for both clinical and commercial needs, and of a pharmaceutical company leading the development of cell and gene therapies medicinal products up to their launch on the market. CELLforCURE is an LFB subsidiary.